SB 728 T

Drug Profile

SB 728 T

Alternative Names: SB 728mR T; SB-728-T; ZFP Therapeutic

Latest Information Update: 19 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sangamo BioSciences
  • Developer Sangamo Therapeutics
  • Class Antivirals; Cell therapies; Gene therapies; T lymphocyte cell therapies; Zinc finger DNA binding proteins
  • Mechanism of Action CCR5 receptor modulators; Gene silencing
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - HIV infections

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 13 Sep 2017 Phase-I/II development is ongoing in Puerto Rico (NCT01543152) (Sangamo Therapeutics pipeline, September 2017)
  • 07 Jul 2017 Sangamo Biosciences completes a phase I/II trial in HIV infections in USA and Puerto Rico (NCT01543152)
  • 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top